Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233524 | 0.81 | GPR119 (0.53) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL1513166 | 0.81 | GPR119 (0.53) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL2447286 | 0.80 | POLB (0.44) | GPR119HPGDALDH1A1 | |
| SCHEMBL2428188 | 0.79 | EED (0.54) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL4465793 | 0.79 | MAPT (0.47) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL19284729 | 0.78 | GPR119 (0.47) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL2422972 | 0.78 | KDM4E (0.48) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL15000897 | 0.77 | GPR119 (0.50) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL16824980 | 0.77 | MAPT (0.48) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL2338827 | 0.77 | GPR119 (0.52) | KDM4EMAPTTHRBGPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550252-B1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2550252-B1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20130324550-A1 | 1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2011119461-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | HTR1A, HTR1D, HTR5A | KDM4E 1169/4885MAPT 1677/4885THRB 988/4885 |
| US-20130324550-A1 | 1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS | HTR1A, HTR1D, HTR5A | KDM4E 1169/4885MAPT 1677/4885THRB 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.